{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:49:41Z","timestamp":1790171381931,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jaad.2017.05.060","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T23:55:21Z","timestamp":1525996521000},"page":"1047-1056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Langerhans cell histiocytosis in children"],"prefix":"10.1016","volume":"78","author":[{"given":"Jolie","family":"Krooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milen","family":"Minkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G.","family":"Weatherall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.05.060_bib1","first-page":"122","article-title":"Langerhans cell histiocytosis: emerging insights and clinical implications","volume":"30","author":"Zinn","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2017.05.060_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/PAT.0000000000000256","article-title":"Langerhans cell histiocytosis: a comprehensive review","volume":"47","author":"El Demellawy","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.jaad.2017.05.060_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2350\/09-05-0651-OA.1","article-title":"Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis","volume":"13","author":"Galluzzo","year":"2010","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.jaad.2017.05.060_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1525-1470.2008.00669.x","article-title":"Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society","volume":"25","author":"Satter","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-8-72","article-title":"Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net","volume":"8","author":"Girschikofsky","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaad.2017.05.060_bib6","first-page":"497","article-title":"Immunohistochemical localization and distribution of S-100 proteins in the human lymphoreticular system","volume":"116","author":"Takahashi","year":"1984","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2017.05.060_bib7","first-page":"296","article-title":"Congenital self-healing reticulohistiocytosis: an underreported entity","volume":"97","author":"Kassardjian","year":"2016","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2017.05.060_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0198-8859(86)90024-8","article-title":"A subset of human cord blood mononuclear cells is similar to Langerhans cells of the skin: a study with peanut agglutinin and monoclonal antibodies","volume":"15","author":"Gothelf","year":"1986","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jaad.2017.05.060_bib9","first-page":"2","article-title":"Congenital self-healing reticulohistiocytosis: concern for a poor prognosis","volume":"18","author":"Larsen","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2017.05.060_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pbc.21690","article-title":"Thymic Langerhans cell histiocytosis mimicking lymphoma","volume":"51","author":"Ya\u011fci","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1808-8694(15)30616-9","article-title":"Rosai-Dorfman disease in the differential diagnosis of cervical lymphadenopathy","volume":"74","author":"Pinto","year":"2008","journal-title":"Braz J Otorhinolaryngol"},{"key":"10.1016\/j.jaad.2017.05.060_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2340\/00015555-0003","article-title":"Clinical spectrum of cutaneous Langerhans' cell histiocytosis mimicking various diseases","volume":"86","author":"Querings","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2017.05.060_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5021\/ad.2016.28.2.262","article-title":"A case of adult generalized cutaneous Langerhans cell histiocytosis","volume":"28","author":"Sun","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0560.1998.tb01760.x","article-title":"Cutaneous Langerhans cell histiocytosis of the genitalia in the elderly: a report of three cases","volume":"25","author":"Meehan","year":"1998","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2017.05.060_bib15","first-page":"123","article-title":"Adult onset Langerhans cell histiocytosis mimicking intertrigo","volume":"34","author":"Edsall","year":"2007","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2017.05.060_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/archpedi.155.7.778","article-title":"Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series","volume":"155","author":"Stein","year":"2001","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jaad.2017.05.060_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2133.1985.tb04858.x","article-title":"Lichen aureus: a localized persistent form of pigmented purpuric dermatitis","volume":"112","author":"Price","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1525-1470.1992.tb00360.x","article-title":"Lichen aureus masquerading as Langerhans cell histiocytosis","volume":"9","author":"Grosshans","year":"1992","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bpobgyn.2014.07.012","article-title":"Hidradenitis suppurativa","volume":"28","author":"Margesson","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2 pt 1","key":"10.1016\/j.jaad.2017.05.060_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0190-9622(87)80132-9","article-title":"Histiocytosis X mimicking the follicular occlusion syndrome: response to local therapy","volume":"16","author":"Dufresne","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/1346-8138.13259","article-title":"Langerhans cell histiocytosis masquerading as hidradenitis suppurativa","volume":"43","author":"Yasuda","year":"2016","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.05.060_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1525-1470.2011.01372.x","article-title":"Cutaneous metastases in neonates: a review","volume":"28","author":"Isaacs","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib23","first-page":"S29","article-title":"Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance","volume":"23","author":"Willman","year":"1994","journal-title":"Br J Cancer Suppl"},{"key":"10.1016\/j.jaad.2017.05.060_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2006.09.001","article-title":"Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease): ten-year experience at Dallas Children's Medical Center","volume":"56","author":"Kapur","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mpo.2950170527","article-title":"Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society","volume":"17","author":"Broadbent","year":"1989","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib27","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mpo.1178","article-title":"Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study","volume":"37","author":"Titgemeyer","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/bjh.13955","article-title":"Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy","volume":"173","author":"Aric\u00f2","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2017.05.060_bib29","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/pde.12829","article-title":"Topical Imiquimod for the treatment of childhood cutaneous Langerhans cell histiocytosis","volume":"33","author":"Dodd","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/pbc.25834","article-title":"Diverse cutaneous presentations of Langerhans Cell histiocytosis in children: a retrospective cohort study","volume":"63","author":"Morren","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/adc.82.6.483","article-title":"Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis","volume":"82","author":"Hoeger","year":"2000","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2017.05.060_bib32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2006.01.061","article-title":"Adult cutaneous Langerhans cell histiocytosis responsive to topical imiquimod","volume":"54","author":"Taverna","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib33","doi-asserted-by":"crossref","first-page":"e829","DOI":"10.1111\/j.1365-2230.2009.03569.x","article-title":"Langerhans cell histiocytosis associated with breast carcinoma successfully treated with topical imiquimod","volume":"34","author":"O'Kane","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13555-016-0117-6","article-title":"Systemic treatment of pediatric psoriasis: a review","volume":"6","author":"Napolitano","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2017.05.060_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.1996.tb03966.x","article-title":"Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient","volume":"23","author":"Sakai","year":"1996","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib36","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/1097-0142(19860515)57:10<1931::AID-CNCR2820571007>3.0.CO;2-G","article-title":"The effect of phototherapies on cutaneous lesions of histiocytosis X in the elderly","volume":"57","author":"Iwatsuki","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1346-8138.1997.tb02740.x","article-title":"Primary cutaneous Langerhans cell histiocytosis treated with photochemotherapy","volume":"24","author":"Kwon","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib38","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1111\/j.1365-2230.2008.03198.x","article-title":"Successful treatment of cutaneous Langerhans' cell histiocytosis with targeted narrowband ultraviolet B phototherapy in an infant","volume":"34","author":"Do","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1346-8138.2010.00959.x","article-title":"Langerhans cell histiocytosis treated with narrow-band ultraviolet B","volume":"38","author":"Aihara","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib40","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/j.1365-2133.2007.08204.x","article-title":"Cutaneous Langerhans cell histiocytosis in an elderly man successfully treated with narrowband ultraviolet B","volume":"157","author":"Imafuku","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib41","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/pde.12240","article-title":"Narrowband ultraviolet B light in Langerhans cell histiocytosis: a case report","volume":"31","author":"Ness","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib42","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2133.2005.07085.x","article-title":"Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data","volume":"154","author":"Black","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2133.2005.06537.x","article-title":"The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: early follow-up data","volume":"152","author":"Man","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2133.2001.04298.x","article-title":"Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate","volume":"145","author":"Steen","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib46","unstructured":"Carroll C, Collier A, Malempati S, Whitlock J. Intermediate-dose methotrexate for recurrent Langerhans cell histiocytosis: a retrospective analysis. Paper presented at: Proceedings of the 24th Annual Meeting of the Histiocyte Society. October 1-3, 2008; Berlin, Germany."},{"key":"10.1016\/j.jaad.2017.05.060_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mpo.2950250204","article-title":"Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis","volume":"25","author":"Womer","year":"1995","journal-title":"Med Pediatr Oncol"},{"issue":"suppl","key":"10.1016\/j.jaad.2017.05.060_bib48","first-page":"AB53","article-title":"Langerhans cell histiocytosis: treatment of cutaneous disease with azathioprine [abstract]","volume":"68","author":"Rao","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib49","first-page":"1020","article-title":"Methotrexate and 6-mercaptopurine in the treatment of Langerhans cell histiocytosis (LCH)","volume":"117","author":"Carstensen","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2340\/00015555756264","article-title":"Langerhans' cell histiocytosis: complete remission after oral isotretinoin therapy","volume":"75","author":"Tsambaos","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2017.05.060_bib51","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1111\/ijd.12252","article-title":"Primary Langerhans cell histiocytosis of the vulva: acitretin as a glucocorticoid-sparing agent","volume":"53","author":"Pedrosa","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib52","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2230.2010.03784.x","article-title":"Langerhans cell histiocytosis in an adult: good response of cutaneous lesions to acitretin","volume":"35","author":"Cardoso","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib53","first-page":"3088","article-title":"Spectacular favorable action of vitamin A in a patient with Hand-Sch\u00fcller-Christian syndrome","volume":"27","author":"Garcia Diaz","year":"1955","journal-title":"Dia Med"},{"key":"10.1016\/j.jaad.2017.05.060_bib54","first-page":"S41","article-title":"Treatment of Langerhans cell histiocytosis\u2014evolution and current approaches","volume":"23","author":"Ladisch","year":"1994","journal-title":"Br J Cancer Suppl"},{"key":"10.1016\/j.jaad.2017.05.060_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mpo.2950230203","article-title":"Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group","volume":"23","author":"Gadner","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib56","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","article-title":"Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification","volume":"111","author":"Gadner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib57","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/ITT.S91058","article-title":"Insights into the pathogenesis of Langerhans cell histiocytosis: the development of targeted therapies","volume":"5","author":"Hutter","year":"2016","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jaad.2017.05.060_bib59","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1067\/mpd.2001.111331","article-title":"A randomized trial of treatment for multisystem Langerhans' cell histiocytosis","volume":"138","author":"Gadner","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2017.05.060_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/mpo.2950210406","article-title":"Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution","volume":"21","author":"Egeler","year":"1993","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12185-016-1993-3","article-title":"Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study","volume":"104","author":"Morimoto","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaad.2017.05.060_bib62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/bjh.13208","article-title":"Up-front therapy for LCH: is it time to test an alternative to vinblastine\/prednisone?","volume":"169","author":"Simko","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2017.05.060_bib63","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.hoc.2015.06.005","article-title":"Clinical characteristics and treatment of Langerhans cell histiocytosis","volume":"29","author":"Monsereenusorn","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2017.05.060_bib64","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1002\/pbc.24436","article-title":"Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis","volume":"60","author":"Abraham","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1705015","article-title":"Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"36","author":"Steiner","year":"2005","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jaad.2017.05.060_bib66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/bmt.2009.245","article-title":"Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan","volume":"45","author":"Kudo","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jaad.2017.05.060_bib67","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.13347","article-title":"Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning","volume":"169","author":"Veys","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2017.05.060_bib68","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib69","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2017.05.060_bib70","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy","volume":"34","author":"H\u00e9ritier","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib71","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1242\/dmm.004010","article-title":"Langerhans cell histiocytosis: malignancy\u00a0or inflammatory disorder doing a great job of imitating one?","volume":"2","author":"Degar","year":"2009","journal-title":"Dis Model Mech Dis Model Mech"},{"key":"10.1016\/j.jaad.2017.05.060_bib72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/11538540-000000000-00000","article-title":"Multisystem Langerhans cell histiocytosis in children: current treatment and future directions","volume":"13","author":"Minkov","year":"2011","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jaad.2017.05.060_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13247","article-title":"Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?","volume":"169","author":"Berres","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2017.05.060_bib74","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/gcc.22247","article-title":"MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis","volume":"54","author":"Nelson","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib75","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2014-05-577361","article-title":"High prevalence of\u00a0somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis","volume":"124","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib76","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib77","doi-asserted-by":"crossref","first-page":"e33891","DOI":"10.1371\/journal.pone.0033891","article-title":"B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease","volume":"7","author":"Satoh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2017.05.060_bib78","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2016-08-733790","article-title":"Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis","volume":"128","author":"Chakraborty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib79","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S1470-2045(17)30031-1","article-title":"Histiocytoses: emerging neoplasia behind inflammation","volume":"18","author":"Haroche","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib80","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2017.05.060_bib81","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamaoncol.2015.0736","article-title":"Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis","volume":"1","author":"H\u00e9ritier","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib82","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.05.060_bib83","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2014.10.045","article-title":"Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis","volume":"73","author":"Haroche","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib84","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.jaad.2014.03.038","article-title":"Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation","volume":"71","author":"Charles","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coph.2015.05.015","article-title":"BRAF inhibitors: the current and the future","volume":"23","author":"Zhang","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jaad.2017.05.060_bib86","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.05.060_bib87","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaad.2017.05.060_bib88","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/MOH.0000000000000256","article-title":"Histiocytic neoplasms in the era of personalized genomic medicine","volume":"23","author":"Durham","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jaad.2017.05.060_bib89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.05.060_bib90","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40265-015-0477-8","article-title":"Cobimetinib: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2017.05.060_bib91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17474124.2017.1264874","article-title":"Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival","volume":"11","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2017.05.060_bib92","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/pbc.20021","article-title":"Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group","volume":"42","author":"Haupt","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2007.12.042","article-title":"Pattern and course of neurodegeneration in Langerhans cell histiocytosis","volume":"153","author":"Wnorowski","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2017.05.060_bib94","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/pbc.21145","article-title":"Reactivation and risk of sequelae in Langerhans cell histiocytosis","volume":"48","author":"Pollono","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2017.05.060_bib95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MPH.0000000000000054","article-title":"Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party","volume":"36","author":"Kim","year":"2014","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221731931X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221731931X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:45:00Z","timestamp":1759272300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221731931X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S019096221731931X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.05.060","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Langerhans cell histiocytosis in children","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(18)30538-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}